Compare Abeona Therapeutics Inc (ABEO) vs Sezzle Inc (SEZL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Sezzle Inc — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Sezzle Inc trades at $167.65 (market cap $5.97B). The key difference: Sezzle Inc is far larger — about 16× Abeona Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| ABEO | SEZL | |
|---|---|---|
Market Cap | $373.32M | $5.97B |
Sector | Health | Technology |
52-Week High | $7.23 | $183.24 |
52-Week Low | $4.17 | $50.97 |
Enterprise Value | $228.22M | $6.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Sezzle (SEZL) trades at $179.05, down 2.29% today, but maintains a strong bullish technical trend with moving averages supporting further upside. Fundamentally, the company exhibits robust profitability with a 30.83% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights product expansion and strong Q1 2026 results, driving positive sentiment.
The outlook remains positive given accelerating revenue growth and raised guidance, though risks include potential securities litigation and high valuation multiples. Analysts are predominantly bullish with a consensus price target of $146.40, suggesting caution near-term, but operational momentum supports long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
